Regulatory Crackdown: Sun Pharma Halted from Producing Eye Drops at Assam Plant Over Quality Concerns
Indian drug regulators have taken decisive action against pharmaceutical giant Sun Pharmaceutical Industries, ordering an immediate cessation of production, sale, and distribution for all ophthalmic medications manufactured at its facility in Assam. The mandate, issued by the Central Drugs Standard Control Organization (CDSCO) in collaboration with the Assam State Drug Control Administration, highlights growing concerns regarding manufacturing standards and patient safety.
A Systemic Failure in Quality Control
The suspension order, delivered on August 20, follows a joint inspection that uncovered significant deficiencies within the plant’s quality assurance protocols. Regulators had previously signaled their intent to scrutinize the facility’s operations after issuing a formal notice on August 10, which demanded an explanation for observed violations. Finding the company’s initial response insufficient to address these critical lapses, authorities opted to halt operations entirely.
Sun Pharma has reportedly submitted a fresh compliance report, which is currently undergoing a rigorous review process. The restrictions will remain in place until regulators are satisfied that the necessary corrective measures have been implemented to meet national pharmaceutical safety standards.
Escalating Recalls and Safety Advisories
This regulatory intervention serves as an escalation of earlier efforts to manage product quality at the site. In July, Sun Pharma initiated a voluntary recall of approximately 11 brands of eye-care products. This move was further complicated by requests from regulators for comprehensive data regarding the recall of 332 batches of ophthalmic suspensions.
The affected range includes commonly prescribed medications such as Lotepred 1% eye drops, Nepalact OD, Nepalact-Z, Brinzotim, and Depopred. Industry estimates suggest that the scope of these recalls could involve hundreds of thousands of individual units, posing a logistical challenge for the company and a potential health risk for the public.
Concerns reached a boiling point in June when the All India Ophthalmological Society issued a formal patient safety advisory. The alert warned that specific batches of Predmet eye drops were potentially contaminated. Dr. Santosh Honavar, secretary of the society, confirmed that infections had been reported in patients who utilized the medication, with subsequent testing of sealed bottles validating the presence of contaminants.
Broader Implications for Sun Pharma
While the ophthalmology segment contributes approximately 3% to Sun Pharma’s total domestic revenue, the recurring nature of these quality issues is a source of concern for both investors and regulators. This incident is not the company’s first brush with international and domestic regulatory scrutiny. Previously, the U.S. Food and Drug Administration (FDA) restricted supplies from Sun Pharma’s facility in Halol, Gujarat, citing similar shortcomings in contamination control.
As the Indian drug regulator continues to review the company’s compliance submissions, the industry remains focused on how the manufacturer will overhaul its internal systems to prevent future lapses. For now, the halt in production at the Assam plant serves as a stark reminder of the stringent expectations placed on pharmaceutical producers to ensure that life-saving eye medications are free from risks that could jeopardize patient vision.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
